
Advances in Hepatorenal Syndrome Research
Untangling Pathophysiology, Improving Diagnostic Strategies, and Leveraging Therapeutic Innovations
- 1st Edition - April 1, 2026
- Latest edition
- Editor: Justin Belcher
- Language: English
Advances in Hepatorenal Syndrome Research: Untangling Pathophysiology, Improving Diagnostic Strategies, and Therapeutic Innovations delivers a thorough exploration of hepato… Read more

Advances in Hepatorenal Syndrome Research: Untangling Pathophysiology, Improving Diagnostic Strategies, and Therapeutic Innovations delivers a thorough exploration of hepatorenal syndrome (HRS), tracing its historical development, prevalence, and changing prognosis. The book addresses the evolving understanding of HRS, examining its shifting clinical recognition and the underlying mechanisms that contribute to disease progression. With a focus on contemporary research, readers are guided through complex pathophysiological concepts, including cardiac dysfunction and inflammatory cytokines, providing a foundational perspective for both clinicians and researchers dedicated to advancing patient care in this challenging field.
The book also emphasizes current diagnostic strategies, such as distinguishing HRS from other conditions and utilizing innovative biomarkers and tests for improved patient assessment. It explores the practical applications of point-of-care ultrasound in evaluating intravascular volume, while also reviewing therapeutic advancements, including vasoconstrictor medications and albumin therapy. Authored by leading experts, this reference stands out for its comprehensive coverage of new diagnostic criteria, emerging treatments, and its role in reshaping the management and outlook of hepatorenal syndrome.
The book also emphasizes current diagnostic strategies, such as distinguishing HRS from other conditions and utilizing innovative biomarkers and tests for improved patient assessment. It explores the practical applications of point-of-care ultrasound in evaluating intravascular volume, while also reviewing therapeutic advancements, including vasoconstrictor medications and albumin therapy. Authored by leading experts, this reference stands out for its comprehensive coverage of new diagnostic criteria, emerging treatments, and its role in reshaping the management and outlook of hepatorenal syndrome.
- Covers the pathophysiology of hepatorenal syndrome and how it sits into the spectrum of acute kidney injury in patients with cirrhosis
- Presents current diagnostic criteria for hepatorenal syndrome and how novel diagnostic tests are moving it from a diagnosis of exclusion to one with objective diagnostic features
- Recommends management of vasoconstrictor therapy and how and when dialysis should be considered
Practicing nephrologists, hepatologists, critical care physicians, hospital pharmacists
1. Historical Perspective, Prevalence and Prognosis
2. Pathophysiology
3. Differential Diagnosis
4. Biomarkers and Novel Diagnostic Tests
5. Point of Care Ultrasound (POCUS)
6. Medical Therapy
7. Dialysis, TIPS and Invasive Therapies
8. Transplantation
9. Risk Factors and Prophylaxis
10. Management of Patients Ineligible for Transplantation
2. Pathophysiology
3. Differential Diagnosis
4. Biomarkers and Novel Diagnostic Tests
5. Point of Care Ultrasound (POCUS)
6. Medical Therapy
7. Dialysis, TIPS and Invasive Therapies
8. Transplantation
9. Risk Factors and Prophylaxis
10. Management of Patients Ineligible for Transplantation
- Edition: 1
- Latest edition
- Published: April 1, 2026
- Language: English
JB
Justin Belcher
Dr. Belcher graduated from Williams College before attending medical  school at Drexel University College of Medicine, where he was elected to Alpha  Omega Alpha, and subsequently completing his internship, residency, and Chief  Residency in Internal Medicine at George Washington University. While  completing his research fellowship in Nephrology at Yale, he received a PhD in  2015 from the Investigative Medicine Program. The primary focus of his  research is acute kidney injury (AKI) in patients with cirrhosis including the  use of novel biomarkers to enhance diagnosis, therapeutic decisions and  prognosis. This interest led to his co-founding HRS-HARMONY, a  multi-disciplinary North American research consortium dedicated to researching  AKI in this setting, with a focus on hepatorenal syndrome.
Affiliations and expertise
Yale University School of Medicine and VA Connecticut Healthcare, USA